Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants
Despite the numerous advantages of allogeneic hematopoietic stem cell transplants (allo-HSCT), there exists a notable association with risks, particularly during the preconditioning period and predominantly post-intervention, exemplified by the occurrence of graft-versus-host disease (GVHD). Risk st...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1327035/full |
| _version_ | 1827348992399245312 |
|---|---|
| author | Maria Iacobescu Cristina Pop Alina Uifălean Cristina Mogoşan Diana Cenariu Mihnea Zdrenghea Alina Tănase Jon Thor Bergthorsson Victor Greiff Mihai Cenariu Cristina Adela Iuga Cristina Adela Iuga Ciprian Tomuleasa Ciprian Tomuleasa Dan Tătaru |
| author_facet | Maria Iacobescu Cristina Pop Alina Uifălean Cristina Mogoşan Diana Cenariu Mihnea Zdrenghea Alina Tănase Jon Thor Bergthorsson Victor Greiff Mihai Cenariu Cristina Adela Iuga Cristina Adela Iuga Ciprian Tomuleasa Ciprian Tomuleasa Dan Tătaru |
| author_sort | Maria Iacobescu |
| collection | DOAJ |
| description | Despite the numerous advantages of allogeneic hematopoietic stem cell transplants (allo-HSCT), there exists a notable association with risks, particularly during the preconditioning period and predominantly post-intervention, exemplified by the occurrence of graft-versus-host disease (GVHD). Risk stratification prior to symptom manifestation, along with precise diagnosis and prognosis, relies heavily on clinical features. A critical imperative is the development of tools capable of early identification and effective management of patients undergoing allo-HSCT. A promising avenue in this pursuit is the utilization of proteomics-based biomarkers obtained from non-invasive biospecimens. This review comprehensively outlines the application of proteomics and proteomics-based biomarkers in GVHD patients. It delves into both single protein markers and protein panels, offering insights into their relevance in acute and chronic GVHD. Furthermore, the review provides a detailed examination of the site-specific involvement of GVHD. In summary, this article explores the potential of proteomics as a tool for timely and accurate intervention in the context of GVHD following allo-HSCT. |
| first_indexed | 2024-03-08T00:21:38Z |
| format | Article |
| id | doaj.art-11bb60ce511a485a9557fdc269cd8a29 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T00:21:38Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-11bb60ce511a485a9557fdc269cd8a292024-02-16T04:53:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-02-011510.3389/fimmu.2024.13270351327035Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplantsMaria Iacobescu0Cristina Pop1Alina Uifălean2Cristina Mogoşan3Diana Cenariu4Mihnea Zdrenghea5Alina Tănase6Jon Thor Bergthorsson7Victor Greiff8Mihai Cenariu9Cristina Adela Iuga10Cristina Adela Iuga11Ciprian Tomuleasa12Ciprian Tomuleasa13Dan Tătaru14Department of Proteomics and Metabolomics, MEDFUTURE Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Pharmaceutical Analysis, Faculty of Pharmacy, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Translational Medicine, MEDFUTURE Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, RomaniaDepartment of Laboratory Hematology, Stem Cell Research Unit, Biomedical Center, School of Health Sciences, University Iceland, Reykjavik, IcelandDepartment of Immunology, University of Oslo, Oslo, NorwayDepartment of Animal Reproduction, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, RomaniaDepartment of Proteomics and Metabolomics, MEDFUTURE Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Pharmaceutical Analysis, Faculty of Pharmacy, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Translational Medicine, MEDFUTURE Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Hematology, Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania0Department of Internal Medicine, Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDespite the numerous advantages of allogeneic hematopoietic stem cell transplants (allo-HSCT), there exists a notable association with risks, particularly during the preconditioning period and predominantly post-intervention, exemplified by the occurrence of graft-versus-host disease (GVHD). Risk stratification prior to symptom manifestation, along with precise diagnosis and prognosis, relies heavily on clinical features. A critical imperative is the development of tools capable of early identification and effective management of patients undergoing allo-HSCT. A promising avenue in this pursuit is the utilization of proteomics-based biomarkers obtained from non-invasive biospecimens. This review comprehensively outlines the application of proteomics and proteomics-based biomarkers in GVHD patients. It delves into both single protein markers and protein panels, offering insights into their relevance in acute and chronic GVHD. Furthermore, the review provides a detailed examination of the site-specific involvement of GVHD. In summary, this article explores the potential of proteomics as a tool for timely and accurate intervention in the context of GVHD following allo-HSCT.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1327035/fullallogenic stem cell transplantationgraft-versus-host-diseasebiomarkerproteomicsbiofluids |
| spellingShingle | Maria Iacobescu Cristina Pop Alina Uifălean Cristina Mogoşan Diana Cenariu Mihnea Zdrenghea Alina Tănase Jon Thor Bergthorsson Victor Greiff Mihai Cenariu Cristina Adela Iuga Cristina Adela Iuga Ciprian Tomuleasa Ciprian Tomuleasa Dan Tătaru Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants Frontiers in Immunology allogenic stem cell transplantation graft-versus-host-disease biomarker proteomics biofluids |
| title | Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants |
| title_full | Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants |
| title_fullStr | Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants |
| title_full_unstemmed | Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants |
| title_short | Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants |
| title_sort | unlocking protein based biomarker potential for graft versus host disease following allogenic hematopoietic stem cell transplants |
| topic | allogenic stem cell transplantation graft-versus-host-disease biomarker proteomics biofluids |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1327035/full |
| work_keys_str_mv | AT mariaiacobescu unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT cristinapop unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT alinauifalean unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT cristinamogosan unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT dianacenariu unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT mihneazdrenghea unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT alinatanase unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT jonthorbergthorsson unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT victorgreiff unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT mihaicenariu unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT cristinaadelaiuga unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT cristinaadelaiuga unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT cipriantomuleasa unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT cipriantomuleasa unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants AT dantataru unlockingproteinbasedbiomarkerpotentialforgraftversushostdiseasefollowingallogenichematopoieticstemcelltransplants |